Perspective Therapeutics, Inc. (CATX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Perspective Therapeutics reported revenue of $0. Net income was -$103.1M, or -$1.40 per diluted share. Operating activities generated -$82.5M of cash, leaving -$95.2M of free cash flow. At fiscal year end, Perspective Therapeutics held $267.0M in total assets against $59.9M in total liabilities, including $30.6M of cash and equivalents.
Open the full interactive Perspective Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Perspective Therapeutics Key Stats
| Share Price | $2.27 |
|---|---|
| Market Cap | $273.9M |
| 52-Week Range | $2.05 – $5.65 |
| Shares Outstanding | 120.7 million (basic, 2026 Q2) |
Perspective Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $9.7M | $10.1M | $10.8M | $1.4M | $0 | $0 |
| Cost of Goods Sold | $4.6M | $4.9M | $6.2M | — | — | — |
| Gross Profit | $5.1M | $5.1M | $4.6M | $1.4M | — | — |
| Operating Income | -$3.5M | -$3.4M | -$7.4M | -$40.9M | -$90.9M | -$113.6M |
| Pre-Tax Income | -$3.4M | -$3.4M | -$7.3M | -$40.1M | -$80.4M | -$104.4M |
| Income Tax | $0 | $0 | $0 | -$2.7M | -$2.1M | -$793,000 |
| Net Income | -$3.4M | -$3.4M | -$7.3M | -$46.5M | -$79.3M | -$103.1M |
| Diluted EPS | -$0.50 | -$0.30 | — | — | -$1.23 | -$1.40 |
Perspective Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$26.0M | -$37.5M | -$26.2M | -$26.8M |
| Diluted EPS | -$0.35 | -$0.51 | -$0.25 | -$0.22 |
Perspective Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.4M | $63.8M | $55.9M | $9.2M | $61.6M | $30.6M |
| Current Assets | $5.5M | $67.3M | $59.3M | $16.8M | $231.2M | $148.4M |
| Total Assets | $8.7M | $70.4M | $64.4M | $97.9M | $341.1M | $267.0M |
| Current Liabilities | $1.6M | $1.8M | $2.3M | $15.7M | $18.2M | $28.7M |
| Total Long-Term Debt | — | — | — | $1.7M | $1.7M | $1.6M |
| Total Liabilities | $3.0M | $3.0M | $3.2M | $22.7M | $50.4M | $59.9M |
| Shareholders' Equity | $5.7M | $67.4M | $61.3M | $75.2M | $290.7M | $207.0M |
Perspective Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.6M | -$2.8M | -$7.7M | -$36.9M | -$18.3M | -$82.5M |
| Cash From Investing | -$287,000 | -$410,000 | -$284,000 | $24.4M | -$218.9M | $41.2M |
| Cash From Financing | $994,000 | $64.7M | $56,000 | $785,000 | $289.4M | $10.3M |
| Free Cash Flow | -$3.9M | -$3.2M | -$8.0M | -$38.0M | -$72.7M | -$95.2M |
Figures from Perspective Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Perspective Therapeutics financials page for every line item.
Perspective Therapeutics Company Profile
| Ticker | CATX |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Seattle, Washington |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000728387 |
Frequently Asked Questions
What was Perspective Therapeutics' revenue in fiscal 2025?
Perspective Therapeutics (CATX) reported revenue of $0 for fiscal 2025.
What is Perspective Therapeutics' annual revenue history?
Perspective Therapeutics' annual revenue by fiscal year: 2020: $9.7M; 2021: $10.1M; 2022: $10.8M; 2023: $1.4M; 2024: $0; 2025: $0.
What was Perspective Therapeutics' net income in fiscal 2025?
Perspective Therapeutics reported net income of -$103.1M for fiscal 2025.
What was Perspective Therapeutics' earnings per share (EPS) in fiscal 2025?
Perspective Therapeutics' diluted EPS was -$1.40 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Perspective Therapeutics generate in fiscal 2025?
Perspective Therapeutics generated -$95.2M of free cash flow in fiscal 2025.
What was Perspective Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Perspective Therapeutics reported revenue of $0.
How much debt does Perspective Therapeutics have?
Perspective Therapeutics reported $1.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Perspective Therapeutics are outstanding?
Perspective Therapeutics reported a weighted average of 120.7 million basic shares outstanding in 2026 Q2.
What is Perspective Therapeutics' market cap?
Based on its latest closing price, Perspective Therapeutics (CATX) has a market capitalization of about $273.9M.
When does Perspective Therapeutics' fiscal year end?
Perspective Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Perspective Therapeutics headquartered?
Perspective Therapeutics lists its business address in Seattle, Washington in its SEC filings.